Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer

Inclusion Criteria

• •Histologically proven epithelial ovarian cancer
• •Progression of disease or relapse after previous therapy with platinum
• •Measurable disease (RECIST 1.1) or elevated CA125 \> 2 times the upper normal limit (UNL) within 3 months and confirmed
• •Age ≥18 years
• •WHO performance status 0-2
• •Adequate bone marrow function: WBC ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l
• •Adequate liver function: bilirubin ≤1.5 x UNL range, ALAT and/or ASAT
• •* 2.5 x UNL (\<5x UNL in case of liver metastases), Alkaline Phosphatase ≤5 x UNL
• •Adequate renal function: the calculated creatinine clearance should be
• •* 50 mL/min
• •Survival expectation \> 3 months
• •Patients must be accessible for treatment and follow-up
• •Written informed consent according to the local Ethics Committee requirements